Commercial-Scale Peptide & Oligo CDMO Manufacturing Solutions
Integrated CDMO services built for true commercial readiness — from early development through multi-ton GMP production.
Our Services
Sinopep Biopharma is a trusted full-service Peptide and Oligo CDMO offering comprehensive end-to-end CMC development and commercial manufacturing solutions for global partners.
Peptide CDMO Services
Comprehensive GMP peptide manufacturing services designed to support projects across all stages of development through to full commercialization.
GMP Oligo Services
We provide end-to-end oligonucleotide manufacturing services — from research-grade to clinical-grade — supporting clients across all phases of development.
FTE Services
Our FTE (Full-Time Equivalent) agreements offer a unique approach for long-term peptide and oligonucleotide manufacturing projects involving multiple targets.
Discovery Services
Sinopep's research-grade peptide and oligonucleotide synthesis services are designed to support our clients' discovery efforts. Chemical design services available.
Generic APIs
Sinopep specializes in the development and manufacturing of high-quality peptide, oligonucleotide, and small molecule active pharmaceutical ingredients (APIs).
Formulation
Finished Dosage Form (FDF) Formulation Services. Oral Solid Dosage Form and Lyophilized Powder Injections. Sterile and Non-sterile preparations also supported.
About Us
Commercial Supply
Sinopep-Allsino Biopharmaceutical Co., Ltd. is a leading worldwide commercial API supplier and full-service CDMO, delivering large-scale GMP manufacturing for peptides, oligonucleotides, and small molecules to support global biopharma partners from development through commercial supply. We provide established peptide capacity of 20–30 metric tons annually, proven commercial-scale production for small molecule generics and NCEs, and our new large-scale GMP oligonucleotide facility in Jiangsu Lianyungang capable of thousands of kilograms per year—including ASOs, siRNA, and advanced conjugates (GalNAc, AOCs, lipid-based, POCs). With FDA-inspected facilities, strong regulatory expertise, and seamless end-to-end capabilities, Sinopep ensures reliable, high-quality, and cost-effective commercial API supply for innovative therapeutics worldwide.
Years Experience
Employees
Capacity (MT/yr)
GMP Faclities
UPCOMING EVENTS
Sinopep would love to meet you at our next event!
Sinopep news
Latest Press Releases from Sinopep
Exhibition at CPHI China 2026
Reflecting on a strong showing at CPHI China, with gratitude to the entire Sinopep team whose collective effort makes moments like this possible.
TIDES 2026 Sinopep Exhibition in Boston
Reflecting on a productive week at TIDES USA, where conversations with leaders across the peptide and oligonucleotide space reinforced the momentum behind this rapidly evolving field.
Sinopep Exhibits at The 21st Drug Discovery Strategic Summit (DDSS)
The 21st Drug Discovery Strategic Summit (DDSS) has wrapped, and we’re still energized by the conversations and connections made at this year’s event.
New Heights
Start your Journey with Sinopep
Comprehensive GMP manufacturing and formulation capabilities to support your projects across all stages—from early discovery and late-phase development through to full commercialization.
Video Introduction
Meet Our Expert Team
Sinopep is a trusted Contract Development and Manufacturing Organization (CDMO) specializing in end-to-end CMC development and cGMP manufacturing of peptide and oligonucleotide APIs for new chemical entities (NCEs). Since 2009, we’ve supported global pharmaceutical innovators across all phases—from early development to commercialization. With a strong regulatory track record, including four successful U.S. FDA inspections, Sinopep adheres strictly to FDA and ICH guidelines. Our integrated services span process development, analytical method development and validation, stability studies, and regulatory support for IND and NDA filings worldwide.
